Pharma Co. Misled Investors On Depression Drug, Suit Says

By Sydney Price · February 10, 2025, 9:20 PM EST

Brain disease drugmaker Neumora Therapeutics Inc. has been hit with a proposed shareholder class action alleging that the company and its initial public offering underwriters failed to disclose prior to the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Chang v. Neumora Therapeutics, Inc. et al

Case Number

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

February 06, 2025

Recent Articles By Sydney

January 22, 2025
Pharma Co. Says Ex-CEO's Alleged Misconduct Is Not Fraud
January 08, 2025
Biotech Co.'s Facility Failures Lost Investors Money, Suit Says
January 02, 2025
Edwards Brass Face Investor Suit Over Heart Valve Sales
December 02, 2024
Investor Alleges Medical Device Co. Misled On FDA Clearance
November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims